Vortex Biosciences is a cell-analytics company with applications in pharma research and oncology. Its VTX-1 system is in sales under an RUO framework, with customers globally in academic research, clinical research and laboratories. The VTX-1 is a a novel liquid biopsy automated instrument (VTX-1), with microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-treatment.
Vortex Biosciences’ main mission is to become the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. The key potential is to revolutionize cancer diagnosis leading to better therapeutic outcomes.
Its technology integrates cancer biology, microfluidic engineering, clinical research and the identification of cancer therapies and drug targets.
‘Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary tumor and have entered the patient bloodstream. These CTCs are known to be the key cause of secondary tumors in patients. As a result, the number and type of CTCs in a patient blood is highly indicative of the status of cancer in that patient. CTCs provide insight into the source of the primary tumor, grade, invasiveness, response to therapy and recurrence.
Level 39,
One Canada Square,
London, E14 5AB
Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.